Major improvements in stocks, including CSL Ltd (ASX: CSL), Ramsay Healthcare Ltd (ASX: RHC), and Cochlear Ltd (ASX: COH) bolstered the sector, following weakness earlier in the year.

Where does the broker see good value now?

Bell Potter has selected seven ASX healthcare shares as its key picks going forward, some of which it says could more than double in value.

One of these is Clarity Pharmaceuticals Ltd (ASX: CU6), which Bell Potter said could have some big news shortly.

The broker said:

For companies with significant clinical readouts over the near-term, it's hard to go past CU6 which is expected to deliver topline data from its two PSMA imaging Phase 3 trials in early CY27. The data from these studies should support a New Drug Application for 64Cu SAR bis PSMA in CY27. Once approved, we expect 64Cu SAR bisPSMA will enter the ~US$3b PSMA imaging market with a highly differentiated label claim to the incumbents.

Bell Potter has a speculative buy rating on the shares with a $6.40 price target.

The broker is also predicting solid share price gains for Mesoblast Ltd (ASX: MSB), which has been preforming well since gaining FDA approval for its drug Ryoncil in late 2024.

Bell Potter said Mesoblast was also progressing a lower back pain drug, with a large potential market.

Its price target for Mesoblast is $4.45.

Other companies which are scaling up in the US are Lumos Diagnostic Holdings Ltd (ASX: LDX) and Aroa Biosurgery Ltd (ASX: ARX).

Bell Potter said regarding these two:

LDX is rapidly scaling its commercial channels ahead of its first flu season in North America, while ARX is driving strong direct growth through Myriad and positioning to capitalise on disruption across the outpatient chronic wound market with Symphony. Both remain well positioned in sizeable US growth opportunities.

Bell Potter has a price target of 25 cents on Lumos and $1.09 on Aroa.

The broker also likes Vitrafy Life Sciences Ltd (ASX: VFY), which it said "has recently emerged with the potential to develop dominant positions across various large cryopreservation markets, but particularly in the blood products segment''.

Bell Potter has a price target of $5.15 on Vitrafy.

The broker said Cogstate Ltd (ASX: CGS) delivered "stellar returns" in FY26, "following significant contract wins across an increasingly diverse range of clinical indications and channel partners''.

It has a price target of $3.70 on Cogstate.

And lastly, Bell Potter is also bullish on Pro Medicus Ltd (ASX: PME), which it said "continues to win ever more business in the US''.

Bell Potter has a price target of $226 on Pro Medicus.

The post 7 ASX healthcare stock picks from Bell Potter appeared first on The Motley Fool Australia.

What did Clarity Pharmaceuticals report?

• Revenue increased 68% to $8.0 million
• Net loss after tax widened to $107.2 million (up 67%)
• Research and development spend rose to $91.1 million
• Liquid assets grew to $178.3 million at year end
• No dividend declared for FY26
• Net tangible assets per share up to 49.9 cents (from 28.1 cents)

What else do investors need to know?

Clarity raised $203 million in fresh capital through a placement at the end of July 2025, strengthening its cash reserves for future clinical trials and commercialisation. The company received a $9.8 million R&D tax incentive refund, highlighting its ongoing investment in Australian radiopharmaceutical research.

The year was marked by significant clinical progress, with flagship prostate and neuroendocrine tumour imaging and therapy candidates advancing through multiple phase II and phase III trials. Manufacturing and supply agreements were expanded to support the anticipated launch of key products.

What did Clarity Pharmaceuticals management say?

Executive Chair Dr Alan Taylor said:

Our strong progress across clinical, regulatory, and manufacturing activities this year lays the foundation for our transition from developer to commercial stage. We remain focused on bringing innovative diagnostic and therapeutic radiopharmaceuticals to patients globally.

What's next for Clarity Pharmaceuticals?

Clarity is prioritising late-stage clinical trials and regulatory submissions in the US for its core copper-based SAR technology platform. The company will also focus on building its commercial infrastructure, supported by expanded manufacturing capabilities and new executive appointments.

Looking ahead, Clarity remains well funded and plans to progress new studies targeting unmet needs in cancer care, while preparing for product launches in the US and other key markets.

Clarity Pharmaceuticals share price snapshot

Over the past 12 months, Clarity Pharmaceuticals shares have declined 33%, trailing the All Ordinaries Index (ASX: XAO), which is flat over the same period.

View Original Announcement

The post Clarity Pharmaceuticals FY26 earnings: Revenue jumps, losses widen as clinical pipeline progresses appeared first on The Motley Fool Australia.

Bell Potter has a bullish share price target on Clarity, which we'll get to shortly.

First, let's look at the latest news from the company.

Clinical trials looking promising

Clarity has developed two radiopharmaceutical compounds called 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA, which are being tested for their utility in treating metastatic castration-resistant prostate cancer (mCRPC).

The company said in early August that 19 participants were included in the most recent assessment of the safety and efficacy of 67Cu-SAR-bisPSMA, with a decline in prostate-specific antigen (PSA) in 74% of participants.

The company added further:

Two new participants in the Cohort Expansion phase of the SECuRE trial who were evaluable at data cut-off achieved complete response as assessed by RECIST. Combined with the five previously announced cases, this brings the total number of participants who achieved complete response or undetectable disease (assessed by RECIST, bone scan and/or PSA) across the 67Cu-SAR-bisPSMA program to seven. These observations demonstrate considerable anti-tumour activity of 67Cu-SAR-bisPSMA following a small number of … treatment cycles in metastatic castration-resistant prostate cancer (mCRPC) patients who have failed multiple lines of therapy.

Clarity Executive Chair Dr Alan Taylor said:

The SAR-bisPSMA product continues to generate an impressive body of evidence in clinical trials and case studies, highlighting the strength of the evidence in both diagnostic and theranostic applications. Most impressively, despite the relatively small numbers of patients enrolled in the SECuRE trial to date, and most having received up to 2 treatment cycles, we see a trend that is impossible to ignore. We continue seeing patients with mCRPC, who have gone through numerous lines of therapy prior to the SECuRE study enrolment, achieve undetectable disease and/or complete response following 67Cu-SAR-bisPSMA treatment.

Dr Taylor said the SECuRE trial would continue to enrol patients, "with Phase III registrational trial planning ongoing based on data that continues to be generated''.

Shares in this ASX biotech looking cheap

Bell Potter analysts said the efficacy data from the trial was "highly encouraging''.

They added:

Ultimately the choice of therapy for mCRPC should come down to survival data first, followed by patient safety and tolerability. Based on this update, which does not yet include overall survival data, we continue to hold the view that 67Cu-SAR-bisPSMA will ultimately yield data that will not only support approval but will become the choice of therapy for oncologists and patients alike.

Bell Potter has a speculative buy rating on Clarity with a price target of $6.40 compared to $2.81 currently.

Clarity is valued at $1.06 billion.

The post This ASX biotech is tipped to more than double in value appeared first on The Motley Fool Australia.

What did Clarity Pharmaceuticals report?

• Over 750 patients and 1,500 scans completed to date in clinical and compassionate-use settings for SAR-bisPSMA products
• Completion of recruitment for the AMPLIFY Phase III imaging trial; recruitment ongoing for the CLARIFY and SECuRE trials
• 8GBq dose of 67Cu-SAR-bisPSMA in metastatic prostate cancer showed 63% PSA50 response and 31% complete/undetectable disease rate
• Favourable safety profile with no treatment-related Grade 4 or higher adverse events in clinical trials
• Multiple head-to-head studies confirming higher lesion detection and true positive rates vs leading standard-of-care PSMA PET agents

What else do investors need to know?

Several major clinical trials have moved into late-stage development, including two registrational Phase III studies in both newly diagnosed and recurrent prostate cancer settings. Real-world use under special access schemes also indicates clinical management changes for many patients, underscoring the agent's practical impact. Importantly, Clarity has secured three separate US FDA Fast Track designations, supporting future regulatory submissions and commercial ambitions in large US markets.

Clarity's comparative studies indicate its proprietary copper-based agents are both more sensitive and flexible than rival PET technologies, with optional next-day imaging giving clinicians more diagnostic confidence. Combined with a solid safety record, these results may underpin broader international adoption if positive results continue.

What's next for Clarity Pharmaceuticals?

Clarity is working towards completion of its pivotal Phase III trials, aiming for regulatory approval of SAR-bisPSMA diagnostics in the US and other major markets. The company is also recruiting for expanded therapeutic studies targeting metastatic, castration-resistant prostate cancer, hoping to demonstrate strong patient outcomes and safety at higher therapeutic doses.

Looking ahead, management sees significant global market opportunities for both imaging and therapeutic agents built on its Australian-developed platform. Ongoing clinical milestones, regulatory updates, and commercial partnerships will be key for investors to watch.

Clarity Pharmaceuticals share price snapshot

Over the past 12 months, Clarity Pharmaceuticals shares have declined 42%, trailing the All Ordinaries Index (ASX: XAO), which has risen 4% over the same period.

View Original Announcement

The post Clarity Pharmaceuticals reports clinical trial milestones appeared first on The Motley Fool Australia.

What did Clarity Pharmaceuticals report?

• 19 participants from the SECuRE trial received the 8 GBq 67Cu-SAR-bisPSMA dose (data cut-off: 20 July 2026).
• 74% achieved a PSA25 response (≥25% reduction in PSA), 63% saw PSA50, 53% reached PSA75, and 26% achieved PSA90.
• 81% (13/16) of evaluable participants showed disease control, including 31% (5/16) complete responses/undetectable disease.
• Five out of seven total complete responses came from the 8 GBq dose cohorts.
• The median number of treatment cycles was two, with mild or moderate adverse events most commonly reported.

What else do investors need to know?

The SECuRE trial is in its Cohort Expansion phase, recruiting patients at the 8 GBq dose in the US. Most participants had previously undergone multiple lines of therapy, highlighting the advanced nature of their disease.

Clarity's proprietary SAR-bisPSMA platform is showing promising anti-tumour activity even after a small number of treatment cycles. The company is also evaluating 8 GBq 67Cu-SAR-bisPSMA in combination with enzalutamide based on positive results from other prostate cancer studies.

What did Clarity Pharmaceuticals management say?

Clarity's Executive Chairperson, Dr Alan Taylor, said:

The SAR-bisPSMA product continues to generate an impressive body of evidence in clinical trials and case studies, highlighting the strength of the evidence in both diagnostic and theranostic applications. Most impressively, despite the relatively small numbers of patients enrolled in the SECuRE trial to date, and most having received up to 2 treatment cycles at 8 GBq, we see a trend that is impossible to ignore. We continue seeing patients with mCRPC, who have gone through numerous lines of therapy prior to the SECuRE study enrolment, achieve undetectable disease and/or complete response following 67Cu-SAR-bisPSMA treatment. Seven participants have now achieved undetectable disease and/or complete response across all cohorts (assessed by RECIST, bone scan and/or PSA), and five of these are from the 8 GBq cohorts. This means that almost a third of all evaluable patients treated at this dose level have achieved a complete response and/or undetectable disease.

What's next for Clarity Pharmaceuticals?

The SECuRE trial will continue recruiting for its Cohort Expansion phase, with planning underway for a Phase III registrational study. Clarity remains committed to developing SAR-bisPSMA for prostate cancer patients who have limited treatment options.

Longer term, Clarity aims to apply its unique theranostic technology to bring new diagnostic and therapeutic choices for prostate cancer, and potentially other cancers as well.

Clarity Pharmaceuticals share price snapshot

Over the past 12 months, Clarity Pharmaceuticals shares have declined 38%, trailing the All Ordinaries Index (ASX: XAO), which has risen 3% over the same period.

View Original Announcement

The post Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose appeared first on The Motley Fool Australia.

What did Clarity Pharmaceuticals report?

• Cash and cash equivalents of $178.3 million at quarter end, providing a robust balance sheet
• Net operating cash outflows of $19.3 million for the June quarter, in line with forecast requirements
• Received $9.7 million Research and Development Tax Incentive refund from the Australian Government
• Signed a significant commercial manufacturing agreement for its lead product, ⁶⁴Cu-SAR-bisPSMA
• Advanced multiple late-stage clinical trials, including completion of recruitment to the Phase III AMPLIFY diagnostic trial
• Grew the team to over 100 employees, with a 45% increase this year

What else do investors need to know?

Clarity continued to progress its late-stage clinical pipeline. The AMPLIFY Phase III trial reached its recruitment target and is on track for key data readouts. The company also announced a new commercial manufacturing agreement with Nucleus RadioPharma, which expands capacity and coverage to prepare for large-scale commercial rollout in the US and Europe.

Board and leadership changes reflect Clarity's focus on governance and expansion, with the appointment of Allison Rossiter as an Independent Director and the transition of Dr Colin Biggin to a full-time COO role. These moves align the board with best practice and bring further diagnostic and commercial expertise.

What did Clarity Pharmaceuticals management say?

Executive Chairperson Dr Alan Taylor said:

We remain well funded with $178.3 million in cash as at 30 June 2026 to support our growth towards the commercial rollout of our products. We again thank our shareholders for their support and look forward to providing further updates on the continued progress of our therapeutic and diagnostic programs.

What's next for Clarity Pharmaceuticals?

Clarity expects to complete its CLARIFY Phase III trial in prostate cancer in 2026, supporting regulatory filings in the US. The AMPLIFY trial data, once available, will also underpin market applications and a potential commercial launch for its next-generation diagnostic product. A Phase III trial in neuroendocrine tumours is also in planning, expanding Clarity's market opportunities.

The company is investing in manufacturing scale and a global distribution network, aiming to secure reliable and widespread access to its radiopharmaceuticals. With its strong funding position, Clarity is well placed to deliver on upcoming milestones and continue developing new cancer treatment options.

Clarity Pharmaceuticals share price snapshot

Over the past 12 months, Clarity Pharmaceuticals shares have declined 45%, trailing the All Ordinaries Index (ASX: XAO), which has risen 2% over the same period.

View Original Announcement

The post Clarity Pharmaceuticals reports clinical progress in June 2026 quarter appeared first on The Motley Fool Australia.

But what was perhaps more compelling in the company's announcement was a first-person account from a patient who had used the company's compound and had benefited greatly from it.

New detection methods being developed

Clarity has developed two radiopharmaceutical compounds called 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA, whose studies to date show they perform well compared with existing detection methods.

The company said it will present various data relating to the compounds at the European Association of Nuclear Medicine (EANM) Annual Congress 2026, which is being held in October in Vienna.

The biotechnology company said regarding the conference:

EANM 2026 Annual Congress is one of the world's leading nuclear medicine conferences and the acceptance of these abstracts is testament to the strength of the data generated by Clarity's products and the promising prospects for SAR-bisPSMA to change the paradigm in the diagnosis and treatment of prostate cancer.

The company said one of its trials, which will be presented, "demonstrated improved diagnostic performance of 64Cu-SAR-bisPSMA next-day imaging vs. 68Ga-PSMA-11 across all key parameters assessed, including mean number of lesions per participant, total number of lesions, true positive rate and proportion of participants with a positive scan''.

The company will also present data from three client case studies, and said the use of its compound "changed planned clinical management in all three patients''.

One of the patients, Steve Hunter, also supplied a testimonial.

Compelling first-person account

Mr Hunter said he was diagnosed with prostate cancer in 2016, and while his initial treatment was quite successful, blood tests revealed in 2023 that his cancer had returned.

He said:

With SOC PSMA imaging currently available, no lesions were detectable. I was informed by more than one doctor that what I had was a micro-metastatic version of prostate cancer; that is, I had a large number of cancers too small to be detected.

Mr Hunter, himself a medical professional with a history including oncology research, approached Clarity with a view to trying its technology.

He said:

The results were beyond my expectations. Three tumours were found and I underwent targeted external beam radiation. Since then, I have repeated this process with Clarity and (Dr Alan Taylor's) support a few times to scan, find and subsequently treat the ensuant small number of tumours that arise, with stereotactic radiation therapy. I am so grateful to Clarity in making these scans available. This approach has proven to be highly successful by allowing me to obtain clear information about my disease and defer requiring ADT therapy and all the associated side effects with this treatment.

Clarity shares were trading 14.1% higher at $2.07.  

The post Why is this ASX biotech charging more than 10% higher? appeared first on The Motley Fool Australia.

This continued a 5-day run of volatility, as Australia's benchmark index continues to jump around significantly day to day. 

In good news, there was several well-known ASX shares that rose significantly: 

• Catapult Sports Ltd (ASX: CAT) shares increased 11%
• Weebit Nano Ltd (ASX: WBT) jumped 13%
• Virgin Australia Holdings Ltd (ASX: VGN) shares rose 9%
• Elevra Lithium Ltd (ASX: ELV) gained 9%
• Clarity Pharmaceuticals Ltd (ASX: CU6) rose 8%

Here's what was behind the gains, and what experts are tipping moving forward. 

Catapult Sports

Catapult Sports shares have now gained a whopping 30% this week. 

Investors are seemingly pleased with the recent FY26 results.

The results included record revenue and strong EBITDA growth. 

The team at Bell Potter were impressed with results, with the broker raising its price target on these ASX shares to $4.65, and retaining its buy recommendation. 

Following yesterday's closing, this updated target indicates 24% further upside. 

Weebit Nano

Weebit Nano shares have exploded in 2026. The digital memory technology company has seen its share price rise almost double since the start of April. 

These ASX shares are now up 300% in the last year. 

This has come on the back of impressive results and capital raising efforts.

At the time of writing, Weebit Nano shares are trading for $6.79 each. 

Forecasts via TradingView indicate there is still moderate upside for this technology stock. 

Analysts forecast an average one year price target of $7.63, which is 12% higher than current levels. 

Virgin Australia

Virgin shares rebounded 9% yesterday after a poor start to the year. 

Its share price remains down 30% year to date, however it appears investors might be beginning to recognise the value in ASX travel shares. 

The sector has been hit hard by surging oil prices, inflation and global conflict in 2026. 

Broker forecasts currently see approximately 45% upside for Virgin shares from current levels. 

Elevra Lithium

Elevra is an emerging lithium producer focused on sourcing and developing the raw materials needed to construct lithium-ion batteries, primarily lithium and graphite.

In 2026 it has benefited from surging oil costs, which has reignited the appeal for alternative energy sources.

After yesterday's 9% gain, this stock is up 400% in the last year. 

Analysts forecasts indicate this rocketing lithium stock can keep climbing. 

The average price target from brokers via TradingView has a one year price target of $15, indicating a further 22% upside. 

Clarity Pharmaceuticals

This radiopharmaceutical company saw its shares rise 8% yesterday. Investors will be hoping this is the start of a rebound, as its share price remains down 26% year to date. 

Last month, Canaccord Genuity placed a price target of $8.41 on the healthcare stock. 

This price target is 200% higher than current levels. 

The post Are these ASX shares a buy, hold or sell after jumping 8% or more? appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Clarity Pharmaceuticals Ltd (ASX: CU6)

The Clarity Pharmaceuticals share price is down almost 8% to $2.89. This follows the announcement of a commercial manufacturing agreement for 64Cu-SAR-bisPSMA with Nucleus Radiopharma. It is an innovative contract development and manufacturing organisation in the radiopharmaceutical industry. Clarity's executive chair, Dr Alan Taylor, said: "Clarity is building a strong foundation with its supply and manufacturing strategy to support a large-scale commercial rollout of 64Cu-SARbisPSMA from day one, with capability to supply not only the entire existing PSMA PET market, but a larger pool of patients that could benefit from our optimised product, given the promising data we have seen in the clinic to date."

Qantas Airways Ltd (ASX: QAN)

The Qantas share price is down 1% to $8.93. This follows the release of a market update from the airline operator today. As was widely expected, Qantas revealed that fuel costs have risen strongly. It now expects jet fuel costs for the second half to be $3.1 billion to $3.3 billion. This is more than double previous expectations. It also advised that net debt is now expected at or above the midpoint, but within Qantas' target range. And while the $300 million interim dividend will be paid on 15 April, its $150 million buyback remains on hold.

Universal Store Holdings Ltd (ASX: UNI)

The Universal Store share price is down 3% to $7.20. This morning, this youth fashion retailer announced the exit of its CEO, Alice Barbery, later this year. However, Universal Store has acted fast and named George Do as her successor. Universal Store's chair, Peter Birtles, said: "On behalf of the Board and the Universal team, I would like to thank Alice for her outstanding leadership of the Company over the past 17 years. During this time, she has overseen the continued strong growth and performance of the Universal Store retail banner, the creation and successful rollout of the Perfect Stranger retail banner and the acquisition of the CTC business."

Westpac Banking Corp (ASX: WBC)

The Westpac share price is down 2.5% to $41.60. Investors have been selling the banking giant's shares following the release of an update on its first-half expectations. The bank advised that: "Balance sheet momentum was solid with lending and deposit growth of 4% and 3% respectively; Core NIM, excluding the timing impact of rate rises, was stable in 2Q26; Ongoing productivity initiatives supported a 2% decline in expenses; and Asset quality metrics improved and the CET1 capital ratio strengthened in 2Q26."

The post Why Clarity, Qantas, Universal Store, and Westpac shares are falling today appeared first on The Motley Fool Australia.

At face value, the news looks positive. Clarity has secured large-scale production capacity for its lead prostate cancer imaging product, and this positions it for a future commercial launch.

So why did the stock fall?

High expectations

It's fair to say that investor expectations for Clarity are sky high, but progress isn't always linear.

Today's announcement from Clarity was actually, on the face of it, quite positive but it did lack concrete dollar figures to provide the required level of 'clarity' (sorry I had to!) on the pathway to commercialisation.

The announcement notes that Clarity will gain access to significant manufacturing capability across the US, including the ability to produce tens of thousands of doses today and potentially hundreds of thousands in the future.

This matters because radiopharmaceuticals are not easy to deliver. These products have short shelf lives and require specialised infrastructure. Companies that can manufacture and distribute reliably have a real advantage.

In simple terms, Clarity is building the foundations to compete at scale.

Despite the strategic progress, investors are forward-looking and thinking of what happens next.

At the moment, Clarity is still a clinical-stage company; its lead product is not yet approved, and it must still complete late-stage trials to secure regulatory approval before generating revenue.

At the same time, expanding manufacturing brings forward costs. Investors often worry about how much capital will be needed and how long it will take to turn that investment into profits.

Another possible factor to explain today's share price movement is the starting point.

Clarity's share price had already performed strongly over the past year, and so when expectations are elevated, even positive developments can trigger selling if they do not materially accelerate the timeline.

In other words, the market was hoping for a step change. Instead, it got a steady step forward.

Foolish bottom line

Zooming out, this announcement is another step forward in Clarity's long-term trajectory.

The company is not just trying to develop a better product; it is trying to ensure it can deliver that product at scale across a large market. If its clinical trials are successful, this manufacturing footprint could become a key competitive strength.

For now, however, investors are balancing that long-term potential against near-term uncertainty, which is understandable.

Clarity shares are now down around 20% year to date, and are up roughly 69% over the past 12 months.

The post Why Clarity Pharmaceuticals shares just fell 5% on today's announcement appeared first on The Motley Fool Australia.

Every now and then, though, it's worth casting your eye over stocks which could outperform the market by a significant amount, and deliver outsized returns.

I've had a look at the recent analyst reports and selected three companies that, at least if the analysts are to be believed, are significantly undervalued at current levels.

Catapult Sports Ltd (ASX: CAT)

Catapult is a global leader in providing technology for professional sports teams to monitor, track, and evaluate their players.

The company held an investor day recently and also put out a trading update in March, which indicated that the company expected management EBITDA to grow by about 50% year on year, "as the company's profitability continues to outpace its strong top-line growth''.

The analysts at Canaccord Genuity attended the investor day and said the company was targeting growth to 5,000 teams in the next two to three years, then 7,000 to 10,000 teams in five to six years.

They added:

Management has identified several greenfield opportunities across global Soccer (lower division levels not using any tech) and Basketball (currently about 100-150 teams weighted to US-based collegiate level), with potential expansion into other US college sports (e.g. Athletics, Ice hockey).

Canaccord has a price target of $8 on Catapult shares, compared with $3.22 now.

Clarity Pharmaceuticals Ltd (ASX: CU6)

Clarity has two Phase III clinical trials in the prostate cancer space that will report this year, which could trigger a major rerating of the company's shares, the analysts at Canaccord Genuity say.

The addressable market for the company's drugs would be about $US2.9 billion annually in the US, Canaccord said, providing the potential for major revenue for the company.

They added:

Should 64Cu-SAR-bisPSMA be approved, and subsequently launch in 2H28, by FY35 we see Clarity generating US$860m in sales, representing 29% share. 

Canaccord has a price target of $8.41 on Clarity shares compared with $3.15 currently.

Global Lithium Resources Ltd (ASX: GL1)

Shaw and Partners has just initiated coverage on this company with a buy recommendation and a very bullish share price target.

Global Lithium is developing the Manna Lithium Project in Western Australia, and released a definitive feasibility study on it in December, envisaging a 14.3-year mine life with a payback period of 3.5 years.

Shaw's report on the company said the Manna project was of "world class scale and quality".

They added:

The project is designed for high efficiency, utilising ore sorting to optimize mill feed and reduce waste. This results in an extremely competitive all in sustaining cost of $1,101/t on our numbers, positioning Manna in the lowest quartile of the global lithium cost curve. This low-cost profile ensures the project remains resilient and commercially viable even during periods of lithium price volatility.

Shaw has a price target of $1.50 on Global Lithium shares compared with the current price of 51.5 cents.

The post 3 ASX shares tipped to grow 100% or more in the next 12 months appeared first on The Motley Fool Australia.

The Canaccord team has a buy recommendation on the stock, and while they've reduced their price target on the company, it's still extremely bullish. We'll get to that later.

Firstly, why is there cause for interest around what the company is doing?

Prostate cancer plans progressing

Canaccord says the major focus for Clarity in the company year are its two Phase III diagnostic trials, "assessing 64Cu-SAR-bisPSMA in PSMA-avid prostate cancer''.

Canaccord goes on to say:

We are expecting readouts from both trials in 2H CY26. If positive, we would anticipate FDA submission and potential launch in 1H CY28. The company has begun bolstering its access to 64Cu in the US, having recently added Theragenics to its existing agreements with SpectronRx and Nusano. With 64Cu supply no longer a question in our minds, our attention turns towards the sales, marketing and distribution side of the equation.

Clarity said in late March that it had signed a large-scale manufacturing agreement for the supply of copper-64 (64Cu) with Theragenics, with the manufacture to take place in Atlanta, Georgia.

Clarity Executive Chair Dr Alan Taylor said at the time:

Clarity is closer than ever to commercialisation of 64Cu-SAR-bisPSMA, with outstanding data recently released from the head-to-head Co-PSMA investigator-initiated trial3 and our announcement on achieving our target number of participants in the Phase III AMPLIFY trial just months since imaging the first patient.

Large addressable market

Canaccord said they had reviewed the US market for PSMA (Prostate-Specific Membrane Antigen) compounds and forecast the 2035 market to be worth US$2.9 billion.

They added:

Should 64Cu-SAR-bisPSMA be approved, and subsequently launch in 2H28, by FY35 we see Clarity generating US$860m in sales, representing 29% share. While there is pushback regarding workflow changes and incumbency, we are encouraged by the growing body of evidence (albeit with smaller patient numbers currently), which delineates 64Cu-SAR-bisPSMA from the current (and developing) players. We see that patients, clinicians, and pharma are all incentivised to find disease at earlier time points, allowing earlier intervention.

Canaccord has a price target on Clarity shares of $8.41, down from $9, with the reduction coming from foreign exchange changes and adjustments to the timelines for the company's portfolio.

This is well north of 100% up on the current share price for Clarity of $3.19. Clarity is valued at $1.14 billion.

The post This ASX healthcare stock could more than double according to Canaccord Genuity appeared first on The Motley Fool Australia.

One such stock is Clarity Pharmaceuticals Ltd (ASX: CU6), according to Bell Potter.

Let's see what the broker is saying about the radiopharmaceuticals company.

What is the broker saying?

Bell Potter highlights that the peer-reviewed paper from the ASX healthcare stock's Co-PSMA trial has now been released. It points out that there have been some very positive things said about the trial by investigators. It explains:

The trial demonstrated that 64Cu-bisPSMA has a significantly higher detection rate compared to a current standard-of-care 68Ga PSMA-11 PET/CT in BCR post radical prostatectomy at PSA levels between 0.2 And 0.75 ng/ml, with consequently higher composite reference standard true positive and lower false negative findings.

This is the first time that a PSMA-targeted imaging agent has demonstrated significantly improved imaging characteristics compared to those currently available, potentially marking an important step forward in imaging technology akin to that seen in the evolution from 18F-Choline/Flucyclovine to PSMA-targeted PET/CT. High praise indeed.

Bell Potter highlights that the investigator concluded that it could be the biggest breakthrough in PSMA imaging since the conversion from 18F-Choline PET imaging. It adds:

64Cu-bisPSMA detected nearly 3x as many tumours in the fossa as 68Ga-PSMA11. The fossa is the anatomical space formerly occupied by the prostate gland prior to prostatectomy and is also the region at highest risk of biochemical recurrence. The vastly improved detection rate in this region is major driver of the investigator's conclusion that 64Cu-SAR-bisPSMA is the biggest break though in PSMA imaging since the conversion from 18F-Choline PET imaging.

Big potential returns

According to the note, the broker has retained its speculative buy rating on the ASX healthcare stock with an improved price target of $6.50.

Based on its current share price of $3.33, this implies potential upside of 95% for investors over the next 12 months.

Commenting on the company, the broker said:

The body of clinical data across Co-PSMA, Propeller and COBRA collectively demonstrate the superiority of 64Cu-bisPMSA at all points across the patient journey with metastatic disease. The company expects to submit the NDA following completion of both AMPLIFY and CLARIFY pivotal studies in the coming months.

The post This ASX healthcare stock could almost double in value according to Bell Potter appeared first on The Motley Fool Australia.

Four ASX shares that are rising more than most today are listed below. Here's why they are racing higher:

4DMedical Ltd (ASX: 4DX)

The 4DMedical share price is up 34% to $6.21. Investors have been buying this respiratory imaging technology company's shares after it made a big announcement. 4DMedical revealed that its CT:VQ technology has been deployed at the Mayo Clinic in the United States. The company's managing director and CEO, Andreas Fouras, commented: "Mayo's deployment is uniquely significant. When the world's number one hospital chooses to use your technology, it sends the strongest possible signal to the entire U.S. healthcare market about the clinical value and readiness of CT:VQ."

Brazilian Rare Earths Ltd (ASX: BRE)

The Brazilian Rare Earths share price is up 8.5% to $4.44. This morning, this rare earths developer revealed that it has secured a Trial Mining Licence from Brazil's National Mining Agency for its Monte Alto project in Bahia. This allows for the extraction of up to 2,000 tonnes per annum of material from the deposit. The company's managing director and CEO, Bernardo da Veiga, said: "Securing the Trial Mining Licence is a significant milestone for Monte Alto and a major step forward in BRE's integrated ore-to-oxides development pathway in Brazil."

Clarity Pharmaceuticals Ltd (ASX: CU6)

The Clarity Pharmaceuticals share price is up 18% to $3.63. This has been driven by news that the radiopharmaceuticals company has signed a large-scale manufacturing agreement with US-based company Theragenics. This gives Clarity access to a 134,000 square foot production facility with 14 cyclotrons capable of producing copper 64 at scale. The company notes that copper 64 offers a key advantage over traditional isotopes. This is due to its longer half-life of around 12.7 hours, which provides a shelf life of up to 48 hours.

Tuas Ltd (ASX: TUA)

The Tuas share price is up 5.5% to $6.33. This morning, this Singapore-based telco released its half-year results for FY 2026. Tuas revealed a 25.5% increase in revenue to S$91.9 million and a 27.2% jump in underlying EBITDA to S$41.1 million. Management advised that this strong growth reflects sustained improvement across all key financial metrics, supported by disciplined cost management and operating leverage.

The post Why 4DMedical, Brazilian Rare Earths, Clarity, and Tuas shares are racing higher today appeared first on The Motley Fool Australia.

Why are Clarity shares rising?

The catalyst for today's move was Clarity's announcement of a large-scale manufacturing agreement with US-based company Theragenics, which gives Clarity access to a 134,000 square foot production facility with 14 cyclotrons capable of producing copper 64 at scale.

Why this matters

This is a meaningful step for a company transitioning from clinical development toward potential commercialisation.

Clarity's lead prostate cancer imaging product is currently in Phase III trials. As the company moves closer to potential approval, the focus increasingly shifts from clinical progress to execution.

Manufacturing capacity is a critical part of that equation.

This agreement strengthens Clarity's supply footprint in the US and builds on its existing network of manufacturing partners. It positions the company to meet potential demand across large oncology markets if its product reaches approval.

Theragenics alone has the capacity to produce enough copper 64 for around 2,000 patient doses per day per cyclotron.

That level of output reflects readiness for commercial scale rather than just clinical supply.

The structural advantage

According to the company, Copper 64 offers a key advantage over traditional isotopes due to its longer half life of around 12.7 hours, enabling a shelf life of up to 48 hours.

This allows for centralised manufacturing and broader distribution, reducing logistical constraints that have historically limited the radiopharmaceutical market.

It also supports a more efficient and scalable operating model, which becomes increasingly important as volumes grow.

What investors should watch

Today's share price reaction reflects growing investor confidence in Clarity's ability to execute beyond the clinical stage.

The company is building the infrastructure required to support a commercial launch, an area that can often become a bottleneck if left too late.

However, the core risk remains unchanged. The lead product is still unapproved, and regulatory outcomes will ultimately determine the size of the opportunity.

For now, though, there is plenty of optimism as Clarity evolves from a clinical stage story into a company preparing for scale.

The post Clarity Pharmaceuticals shares are up 12% today. Here's what's driving the move appeared first on The Motley Fool Australia.

These shares can offer portfolio diversification, drive high margins, and some of them have huge potential upside.

Here are three ASX healthcare stocks on my radar this week, and analysts are tipping upside well over 100% over the next 12 months.

Pro Medicus Ltd (ASX: PME)

The beaten-down medical imaging technology stock has dropped another 1.7% in Wednesday afternoon trade, to $125.69 a piece. The decline is part of a long string of declines off the back of sector-wide headwinds, which have seen the share price crash 62% from an all-time high recorded in mid-2025.

Sentiment didn't improve when the company posted a record-breaking half-year FY26 result in mid-February. Its revenue was up 28%, and profit jumped nearly 30%, but it still missed investors' high expectations.

But Pro Medicus has won several contracts so far in 2026, including two $40 million five-year contract renewals with its wholly owned US subsidiary, Visage Imaging, earlier this month.

I think the stock is trading well below value right now. And analysts are tipping potential for a 139% upside to $300 per share over the next 12 months.

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix shares are racing higher on Wednesday, recovering some losses seen during a sharp sell-off last year.

Despite several recent headwinds, it looks like Telix shares are finally rebounding. The positive sentiment started when it filed a key regulatory approval in Europe. News of positive results from its Global Phase 3 ProstACT study last week, followed by an announcement that the company has resubmitted its New Drug Application (NDA) to the US FDA for its brain cancer imaging candidate TLX101-Px (Pixclara®), has seen investors flock to the stock.

Analysts tip the ASX healthcare stock to jump 156% to $31.59 a piece over the next 12 months.

Clarity Pharmaceuticals Ltd (ASX: CU6)

The clinical-stage radiopharmaceutical company's shares jumped higher this week on the back of good news about the development of new trial data for its prostate cancer imaging technology. The findings will be used as a basis to form a new drug submission to the FDA.

It's good news after Clarity shares suffered from volatility over the past five months, fluctuating anywhere between $5.70 and $2.73. 

Analysts are excited about the prospects for growth of the ASX healthcare stock's business fundamentals and share price over the next 12 months. They have a consensus buy rating with a maximum target price of $9. That implies a potential 157% upside at the time of writing.

The post 3 ASX healthcare stocks tipped to soar over 100% higher this year appeared first on The Motley Fool Australia.

Let's see what they are saying about the three named below, which have released updates in recent days. Here's what you need to know:

Clarity Pharmaceuticals Ltd (ASX: CU6)

Bell Potter has been pleased with recent study data relating to this radiopharmaceutical company's 64Cu-SAR-bis-PSMA PET product. It highlights that it is significantly outperforming Ga-PSMA-11 PET in the detection of biochemical recurrence in men with very low PSA levels.

As a result, the broker has reaffirmed its speculative buy rating and $6.40 price target on its shares. It said:

The stage is now set for a readout from the approval study for 64Cu-SAR-bisPSMA (AMPLIFY) which has now ceased accepting new patient consents and is practically fully enrolled (n=220). The Co-PSMA data along with data from COBRA and anticipated findings from AMPLIFY will form the basis of submission of a new drug application to be submitted to the FDA.

CU6 has three fast track designations for the SAR-bisPSMA agent which includes patients with BCR of prostate cancer following definitive therapy. The company is well funded with cash in excess of $226m at 31 Dec 2025.

New Hope Corporation Ltd (ASX: NHC)

This coal miner disappointed analysts at Morgans with its half-year results. The broker highlights that its net profits were much softer than expected.

In light of this, the broker has retained its hold rating with a $5.00 price target. It said:

Overall result missed expectations, with underlying NPAT of A$54m materially below MorgansF (A$63m) and Visible Alpha consensus (A$78m), despite EBITDA of A$215m coming in line with expectations. NHC declared a fully franked 10c dividend, beating MorgansF (8c) and consensus (6c) estimates.

With an increasing production profile and material upside potential in coal prices, NHCs outlook remains positive. We maintain a HOLD rating with a target price of A$5.00ps.

Orica Ltd (ASX: ORI)

Morgans was pleased with this commercial explosives and blasting systems company's trading update.

It was also pleased to see its CF Industries litigation settled and the strengthening of its US operations with an acquisition.

This has seen Morgans reiterate its buy rating with an improved price target of $25.35. It said:

ORI's trading update was slightly stronger than we expected. It also announced the settlement of its litigation with CF Industries and the acquisition of its US explosives JV partner, Nelson Brothers, strengthening its US operations. Higher AUD and Indonesia's coal production quotas have seen us make minor revisions to our FY26 forecasts but the acquisition has upgraded FY27/28.

With leverage to attractive industry fundamentals, market leading positions, solid earnings growth, proven management team and strong balance sheet, we reiterate our BUY rating with a new price target of A$25.35.

The post Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares appeared first on The Motley Fool Australia.

Let's back up and provide a little context. 

Company overview and trial update

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theranostics (TCT) for the imaging and treatment of selected cancers. 

In particular the company works on identification of certain cancer biomarkers. They develop technology to target those biomarkers with either small molecules or monoclonal antibodies.

The company has been engaged in a clinical study. 

The study is evaluating the diagnostic performance of the company's 64Cu-SAR-bisPSMA PET imaging agent. The agent aims to detect recurrent prostate cancer in men with rising prostate-specific antigen (PSA) levels after initial treatment.

Importantly, the study compared Clarity Pharmaceuticals' imaging technology with a current standard-of-care PSMA PET scan.

Yesterday, the company released an announcement that the agent showed a 71% true positive rate, meaning that 7 out of 10 positive scans were confirmed as cancer, compared with only 29% for the older agent, 68Ga-PSMA-11.

The biggest improvements were in detecting cancer in the prostate fossa and lymph nodes, where treatment can be curative.

The false negative rate was just 21% for 64Cu-SAR-bisPSMA, versus 65% for 68Ga-PSMA-11, confirming its higher accuracy and reliability.

Interestingly, this ASX healthcare stock shot 17% higher on the news, before cooling off and actually finishing the day down 6%. 

Bell Potter provides an update

Following the announcement, Bell Potter released updated guidance on the ASX healthcare stock. 

The broker said Professor Louise Emmett presented key findings from the Co-PSMA study on Monday in London at the European Association of Urology annual conference.

The headline data had been released previously and showed that 64Cu-SARbisPSMA PET outperformed 68Ga-PSMA-11 PET in the detection of biochemical recurrence in men with very low PSA levels.

The totality of the data confirms 64Cu SAR bisPSMA is vastly more accurate for the detection of early stage BCR, particularly in men with very low PSA levels consistent with low tumour burden.

The stage is now set for a readout from the approval study for 64Cu-SAR-bisPSMA (AMPLIFY) which has now ceased accepting new patient consents and is practically fully enrolled (n=220). The Co-PSMA data along with data from COBRA and anticipated findings from AMPLIFY will form the basis of submission of a new drug application to be submitted to the FDA.

Upside in tact 

Included in the report from Bell Potter was a speculative buy recommendation. 

The broker also maintained its price target of $6.40. 

From the recent closing price of $3.40, this indicates an upside of 88.2%. 

The false negative rate (i.e. no cancer on the PET image, positive on biopsy/pathology) was 21% for 64Cu-SAR-bisPSMA vs 65% for 68Ga-PSMA-11, again demonstrating CU6's product as clearly superior. 

We conclude that 64Cu-SARbisPSMA also provides a far more satisfactory level of specificity.

The post Exciting clinical news for this ASX healthcare stock earns it a buy recommendation  appeared first on The Motley Fool Australia.

Will the market be able to build on this on Wednesday? Here are five things to watch:

ASX 200 set to rise

The Australian share market looks set to rise again on Wednesday following a good night on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 9 points or 0.1% higher. In late trade in the United States, the Dow Jones is up 0.2%, the S&P 500 is up 0.3% and the Nasdaq is 0.5% higher.

Oil prices rise

ASX 200 energy shares including Beach Energy Ltd (ASX: BPT) and Santos Ltd (ASX: STO) could have a good session on Wednesday after oil prices pushed higher overnight. According to Bloomberg, the WTI crude oil price is up 2.5% to US$95.85 a barrel and the Brent crude oil price is up 3% to US$103.26 a barrel. This was driven by concerns over the lack of support for US plans to escort tankers through the Strait of Hormuz.

Buy Clarity shares

The team at Bell Potter thinks Clarity Pharmaceuticals Ltd (ASX: CU6) shares are good value at current levels. This morning, the broker has retained its speculative buy rating and $6.40 price target on the radiopharmaceuticals company's shares. It said: "The stage is now set for a readout from the approval study for 64Cu-SAR-bisPSMA (AMPLIFY) which has now ceased accepting new patient consents and is practically fully enrolled (n=220). The Co-PSMA data along with data from COBRA and anticipated findings from AMPLIFY will form the basis of submission of a new drug application to be submitted to the FDA."

Gold price flat

ASX 200 gold shares such as Newmont Corporation (ASX: NEM) and Northern Star Resources Ltd (ASX: NST) could have a subdued session on Wednesday after the gold price traded flat overnight. According to CNBC, the gold futures price is trading at US$5,003.8 an ounce. Traders appear undecided where gold is going next and are waiting for the upcoming US Federal Reserve meeting.

New Hope shares upgraded

New Hope Corporation Ltd (ASX: NHC) shares have been upgraded by analysts at Bell Potter. This morning, the broker has taken its sell rating off the coal miner's shares after lifting them to a hold rating with a $4.50 price target. It said: "We upgrade to a Hold recommendation and apply a 5% premium to our sum of the parts valuation with energy security concerns exacerbated by recent geopolitical issues. NHC's low-cost operations will continue to underpin margins through the coal price cycle, funding capital expenditure commitments and supporting shareholder returns. Beyond ramp-up of New Acland Stage 3, we see a limited organic production growth pipeline and believe NHC may participate in industry consolidation."

The post 5 things to watch on the ASX 200 on Wednesday appeared first on The Motley Fool Australia.

In early trade, the ASX 300 stock jumped as much as 17% to $4.26 before pulling back.

At the time of writing, the clinical-stage radiopharmaceutical company's shares are still up around 5%.

Why is this ASX 300 stock jumping?

Investors appear to be responding positively to an update from the company regarding new trial data for its prostate cancer imaging technology.

The company revealed that results from the Co-PSMA study were presented at the European Association of Urology (EAU) Annual Congress 2026 in London. The data has also been accepted for publication in the European Urology journal.

The trial evaluated Clarity's diagnostic product, 64Cu-SAR-bisPSMA, in patients experiencing biochemical recurrence of prostate cancer after surgery.

Importantly, the study compared the ASX 300 stock's imaging technology with a current standard-of-care PSMA PET scan.

The results showed that Clarity's agent detected significantly more cancer lesions than the standard scan. Across the study participants, the new imaging approach identified 63 lesions compared with 24 detected using the standard-of-care method.

In addition, 78% of patients had a positive scan using 64Cu-SAR-bisPSMA compared with 36% using the existing imaging agent, highlighting a potential improvement in detecting recurrent prostate cancer.

The study also showed a higher true positive rate and lower false negative rate for the company's imaging technology.

Why this matters

Detecting prostate cancer recurrence earlier and more accurately can significantly influence treatment decisions.

According to the trial data, the improved imaging results led to changes in planned patient management in 44% of participants, with many switching from surveillance to targeted radiotherapy.

These findings add to the growing body of evidence supporting the SAR-bisPSMA platform, which is designed as a targeted copper theranostic. This technology has the potential to be used both for cancer imaging and treatment depending on the isotope used.

Looking ahead, the company intends to combine results from this study with data from other trials, including the Phase II COBRA study and the Phase III AMPLIFY trial.

Together, these results are expected to support a future regulatory submission to the US Food and Drug Administration (FDA) for approval of 64Cu-SAR-bisPSMA in patients with recurrent prostate cancer.

The ASX 300 stock's executive chair, Dr Alan Taylor, commented:

The extraordinary quality of the academic research is coupled with the feverish pace of commercialisation where our registrational Phase III trials, AMPLIFY and CLARIFY, are nearing completion. We have recently shared that AMPLIFY reached its target number of participants with rising or detectable PSA after initial definitive treatment at clinical sites across the US and Australia in just 9 months since imaging the first patient, and we look forward to collecting and analysing the final study data.

Combined with results from the Co-PSMA and COBRA trials, we believe it will constitute a compelling application for approval of 64Cu-SAR-bisPSMA by regulatory authorities for the BCR indication.

The post Why is this ASX 300 stock rocketing 17% today? appeared first on The Motley Fool Australia.